NCT05505877 2022-08-18Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid TumorsShanghai Gopherwood Biotech Co., Ltd.Phase 1/2 Unknown160 enrolled